Dr Alana Thackray
- Assistant Research Professor in Molecular Pathology and Viral Immunity
Contact
Connect
About
My basic research interests are concerned with molecular pathology, diagnosis and therapy of conventional and non-conventional pathogens, including viruses and prions. I am currently investigating the molecular nature of the infectious prion agent associated with transmissible spongiform encephalopathies such as scrapie of sheep, BSE of cattle, CWD of cervids and CJD of humans. I am interested in the interactions of pathogens with the immune system, in particular, peripheral prion pathogenesis and prion neuroinvasion.
My research work has involved the generation of novel anti-PrP monoclonal antibodies to probe the structure of PrPC and PrPSc; the generation of recombinant PrP protein for biophysical and biochemical analysis and resultant computational modelling to predict prion protein structure. In addition, my projects involve the use of novel gene knock-out and transgenic mice, cell culture, flow cytometry, immunohistochemistry, in situ hybridisation, RT-PCR, SDS-PAGE, western blotting, protein misfolding cyclic amplification (PMCA), conformational-dependent immunoassays (CDI) and more recently confocal microscopy and RNASeq analysis. I am actively involved in the development and commercialisation of molecular reagents for prion research and a prion diagnostic test. I also have considerable experience in research into the pathogenesis and chemotherapy of herpes viruses both in vivo and in vitro, using prophylactic and therapeutic strategies.
Analysis of the biochemical pathways associated with ovine prion formation, clearance, and neurotoxicity will be helped by the application of new tractable animal models of this condition. Use of a genetically well-defined host will allow identification of genetic modifiers of ovine prion disease pathogenesis, providing the potential for development of new diagnostic markers and therapeutic targets for prion diseases in general. The fruitfly Drosophila melanogaster has been used to model a number of human neurodegenerative diseases and a major strength of Drosophila model systems is the ability to rapidly generate transgenic flies that express heterologous proteins in a tissue-specific manner. Genetic pathways are extensively conserved between mammalian and Drosophila genomes, which allows fly models of neurodegenerative disease to identify candidate genetic modifiers of the condition in the host species. At present, we are investigating Drosophila as a new animal model for a variety of prion disorders so we can generate a more tractable invertebrate model of transmissible mammalian prion disease.
Research
My basic research interests are concerned with molecular pathology, diagnosis and therapy of conventional and non-conventional pathogens, including viruses and prions. I am currently investigating the molecular nature of the infectious prion agent associated with transmissible spongiform encephalopathies such as scrapie of sheep, BSE of cattle and CJD of humans. I am interested in the interactions of pathogens with the immune system, in particular, peripheral prion pathogenesis and prion neuroinvasion. Analysis of the biochemical pathways associated with ovine prion formation, clearance, and neurotoxicity will be helped by the application of new tractable animal models of this condition. Use of a genetically well-defined host will allow identification of genetic modifiers of ovine prion disease pathogenesis, providing the potential for development of new diagnostic markers and therapeutic targets for prion diseases in general. The fruitfly Drosophila melanogaster has been used to model a number of human neurodegenerative diseases and a major strength of Drosophila model systems is the ability to rapidly generate transgenic flies that express heterologous proteins in a tissue-specific manner. Genetic pathways are extensively conserved between mammalian and Drosophila genomes, which allows fly models of neurodegenerative disease to identify candidate genetic modifiers of the condition in the host species. At present, we are investigating Drosophila as a new animal model of ovine scrapie in order to provide a more tractable invertebrate model of transmissible mammalian prion disease. My research work has involved the generation of novel anti-PrP monoclonal antibodies to probe the structure of PrPC and PrPSc; the generation of recombinant PrP protein for biophysical and biochemical analysis and resultant computational modelling to predict prion protein structure. In addition, my projects involve the use of novel gene knock-out and transgenic mice, cell culture, flow cytometry, immunohistochemistry, in situ hybridisation, RT-PCR, SDS-PAGE, western blotting, protein misfolding cyclic amplification (PMCA), conformational-dependent immunoassays (CDI) and more recently confocal microscopy. I am actively involved in the development and commercialisation of molecular reagents for prion research and a prion diagnostic test. I also have considerable experience in research into the pathogenesis and chemotherapy of herpes viruses both in vivo and in vitro, using prophylactic and therapeutic strategies.
Main collaborators- Dr Candace Mathiason (Professor of Pathobiology at Colorado State University, USA)
- Dr Olivier Andréoletti (INRA Research Director, Ecole Nationale Vétérinaire de Toulouse, University of Toulouse, France)
- Dr Timm Konold (Veterinary Research Officer, Animal Plant and Health Agency, Weybridge, UK)
- Dr John Spiropoulos: (Senior Research Pathologist, Animal Plant and Health Agency, Weybridge, UK)
- Professor Joaquin Castilla (Director of the Prion Laboratory at the CIC bioGUNE, Spain)
- Professor Hermann Schätzl (Prion Biology and Immunology Head, Calgary Prion Research Unit, University of Calgary, Canada)
- Professor Michael Klein (University of Würzburg, Germany)
- Dr Walker Jackson (Associate Professor, Linköping University, Sweden)